Literature DB >> 26474412

Plasma Procalcitonin Concentration in Healthy Horses and Horses Affected by Systemic Inflammatory Response Syndrome.

F Bonelli1, V Meucci1, T J Divers2, E Jose-Cunilleras3, M Corazza1, R Tognetti1, G Guidi1, L Intorre1, M Sgorbini1.   

Abstract

BACKGROUND: The diseases most frequent associated with SIRS in adult horses are those involving the gastrointestinal tract. An early diagnosis should be the goal in the management of horses with SIRS.
OBJECTIVE: The objective of this study was to evaluate the plasma procalcitonin (PCT) concentration in healthy and SIRS horses to assess differences between the two groups. ANIMALS: Seventy-eight horses (30 healthy and 48 SIRS).
METHODS: Prospective in vivo multicentric study. Horses were classified as SIRS if at least 2 of the following criteria were met: abnormal leukocyte count or distribution, hyperthermia or hypothermia, tachycardia, tachypnea. Healthy horses showed no clinical or laboratory signs of SIRS. Plasma PCT concentrations were measured with a commercial ELISA assay for equine species. Results were expressed as mean±standard deviation. T-test for unpaired data was performed between healthy and SIRS group. SIRS group was divided in 4 subgroups and t-test was performed between healthy versus each subgroup.
RESULTS: PCT concentrations in healthy and SIRS horses were 18.28 ± 20.32 and 197.0 ± 117.0 pg/mL, respectively. T-test showed statistical differences between healthy versus SIRS group and between healthy versus all subgroups. CONCLUSIONS AND CLINICAL IMPORTANCE: Results showed an increase in PCT concentration in SIRS horses as previously reported in humans and dogs. PCT could be used as a single assay in equine practice for detection of SIRS.
Copyright © 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

Entities:  

Keywords:  Biomarker; Diagnostic Test; Equine

Mesh:

Substances:

Year:  2015        PMID: 26474412      PMCID: PMC4895682          DOI: 10.1111/jvim.13640

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


lipopolysaccharide systemic inflammatory response syndrome procalcitonin potassium ethylene diamine tetraacetic relative centrifugal force coefficient of variation beats per minute breaths per minute Endotoxins (lipopolysaccharides, LPS) are present in large quantities in the large bowel of horses, but are harmless as long as they remain within the intestinal lumen. Equine gastrointestinal diseases involving hypersecretion of fluid, motility disturbances, altered microbial flora, local stasis, ischemia, inflammation, and impaired mucosal barrier may lead to absorption of endotoxin, bacterial products or both through the compromised mucosa into the bloodstream. Endotoxemia induces release of acute phase proteins and cytokines that may result in severe organ dysfunction and death.1 The physiologic changes associated with this inflammatory activation are alteration in heart and respiratory rate, body temperature, mucous membrane status, and capillary refill time. Recently, some authors have supposed that the term systemic inflammatory response syndrome (SIRS), rather than endotoxemia, should be used to describe the clinical status of “endotoxemic” horses. The diseases that have been associated with SIRS in adult horses are especially those involving the gastrointestinal tract, such as the inflammatory intestinal diseases and strangulating obstructions.1 An early diagnosis should be the goal in the management of SIRS patients, allowing starting an adequate treatment in an early stage.2, 3 Due to the importance of procalcitonin (PCT) as biomarker of SIRS in human medicine,3 the aim of the present work was to evaluate the plasma PCT concentration in healthy and SIRS horses to evaluate the differences between the two groups.

Materials and Methods

The present in vivo multicentric experimental trial in clinical setting was approved by the Institutional Animal Care and Use Committee of the University of Pisa, University of Barcelona and Cornell University. A total of 78 horses were included in the present prospective study. Thirty were healthy horses from different farms. Thirteen/30 (43%) were females, 11/30 (36%) geldings, and 6/30 (20%) stallions. Mean age was 9.8 ± 5.4 years old. Forty‐eight were sick horses referred to three different veterinary teaching hospitals providing secondary health care. The following data were recorded both for healthy and sick animals, in order to classify horses in healthy and SIRS1 groups: presence of abnormal leukocyte count or distribution as leukopenia, leukocytosis or >10% band neutrophils (reference intervals: 5.4–14.3 × 103 μL),4 hyperthermia or hypothermia (reference intervals: 37.2–38.3°C),5 tachycardia (reference intervals: 28–44 bpm),5 tachypnea (reference intervals: 8–15 bpm).5 All the 30 healthy horses presented a normal physical examination and clinicopathologic data within reference ranges, thus they were included in the control group. Horses with 2 or more criteria were included in the SIRS group.1 Ten/48 (21%) sick horses were stallions, 18/48 (38%) geldings, and 20/48 (41.5%) females. Mean age was 10.3 ± 6.7 years old. The horses were of different breeds: Standardbred (n = 8), Pure Spanish Horse (n = 7), cross‐breed (n = 6), Quarter Horse (n = 6), Thoroughbred (n = 6), Ponies (n = 4), Italian saddle horse (n = 3), Paint Horse (n = 3), Arabian (n = 1), Appaloosa Horse (n = 1), Belgian horse (n = 1), Hanoverian horse (n = 1), and Warmblood (n = 1). An owner's written consent was obtained for collection of plasma for all the horses included in this study. Retrospectively, SIRS horses were divided into 4 subgroups based on nature of the pathological process: 18/48 (38%) strangulated intestinal lesion, 13/48 (27%) nonstrangulated intestinal lesion, 11/48 (23%) diarrheas or colitis, and 6/48 (13%) pleuropneumonia. All horses were submitted to a complete physical examination and blood collection for CBC evaluation and plasma PCT analysis. Blood samples for CBC and PCT concentrations were collected from the jugular vein using a sterile syringe and 16G needle. Each blood sample was divided in two aliquots: a 1 ml aliquot was collected in a potassium ethylene diamine tetraacetic (K2EDTA) test tube and analyzed by a cell countera within 5 minutes after the collection. A second 2.5 mL aliquot was collected in heparinized‐tubes and immediately centrifuged at 2100 relative centrifugal force (RCF) for 10 min. The harvested plasma was placed in sterile tubes, frozen at −18°C and analyzed in a single batch within 3 months. There was no intravenous administration of calcium before blood collection, so as to not influence plasma PCT concentrations. PCT concentrations were determined with a commercial kit for equine species.b The intra‐assay coefficient of variation was determined from 10 replicates of equine plasma samples containing low and high PCT concentrations. These samples were obtained by addition of standard PCT in equine blank samples. The interassay coefficient of variation was determined from values obtained by repeating the analysis of duplicate samples with low and high PCT concentrations in 5 different assays. To establish the detection limit for equine plasma PCT, we performed repeated PCT measurements using equine samples with low PCT concentrations (<10.0 pg/mL). Samples were measured in 10 replicates in a single assay and in 5 different assays. The intra‐ and interassay coefficient of variations were both <15%, the limit of detection of the method was 10 pg/ml. Descriptive data are reported as mean ± standard deviation. Kolmogorov–Smirnov test was applied to verify data distribution. T‐test for unpaired data was performed to verify differences in plasma PCT concentration between healthy versus SIRS group, and between healthy versus each subgroup. Significance level was set at P < .05. A commercial statistical software was used.c

Results

All horses included in the healthy group showed no clinical and clinico‐pathologic signs of SIRS, while all the 48 sick horses presented 2 or more signs of SIRS. The plasma PCT concentration was 18.28 ± 20.32 pg/mL and 197.0 ± 117.0 pg/mL in healthy and SIRS group, respectively, while plasma PCT concentrations in various subgroups were reported in Table 1. T‐test for unpaired data showed a statistical difference between healthy versus SIRS group and between healthy versus all subgroups.
Table 1

Plasmatic PCT concentrations, expressed as mean ± SD, obtained in the 4 subgroups

DiseasePCT (pg/mL) (X ± SD)P versus healthy group
Strangulated intestinal lesion232 ± 155<0.0001
Nonstrangulated intestinal lesion148 ± 79<0.0001
Diarrhea or Colitis168 ± 91<0.0001
Pleuropneumonia217 ± 95<0.0001
Plasmatic PCT concentrations, expressed as mean ± SD, obtained in the 4 subgroups

Discussion

PCT appears to be an early marker of SIRS caused by bacterial infections and associated products in human medicine.3, 6 PCT originates from the CALC‐I gene transcription and calcitonin‐mRNA translation. In healthy patients, the transcription of the CALC‐I gene is restricted to neuroendocrine cells in the thyroid gland and the lung and healthy individuals have very low serum concentrations.3, 6 During a state of infection the expression of the CALC‐I gene is up regulated and PCT is released from many tissues and cell types in the body in laboratory animals, dogs and horses, as well as in human patients.3, 6, 7, 8 Moreover, plasma PCT concentration rises rapidly within 3‐6 h, especially in response to bacterial infection and endotoxemia, seeming to be also an early marker of bacterial infection and endotoxemia in human patients.3, 6 Plasma PCT concentration was lower in healthy horses than in SIRS ones. Our results are in line with earlier studies performed in equine, canine, and human species.3, 6, 9, 10, 11 The mean plasma PCT concentration reported in this study, both for healthy and SIRS group, were lower than those reported in another study performed in 29 horses (24 healthy horses and 5 septic horses).10 The dissimilarity might be due to the different PCT ELISA kit used: in our study, an equine PCT ELISA kit assay for PCT determination was used, while Rieger and colleagues (2014)10 have used an ELISA assay in which, human antibodies were directed against equine PCT. Plasma PCT levels were similar to those reported in foals and plasmatic PCT concentrations were statistically different between healthy versus SIRS groups both in foals and in adults, confirming that PCT increases during SIRS.11 PCT levels in horses in this study were generally lower than levels reported in humans with SIRS.3, 6 This dissimilarity might be related to the different species studied, less severe inflammation in the studied horses, or possibly endotoxin tolerance.12 Moreover, Yilmaz and colleagues (2008)9 evaluated the changes in PCT concentrations in dogs after administration of endotoxin, which resulted lower than our results. This difference could be related to the species studied (dog versus horse) and to the different assay used. PCT concentrations obtained in all subgroups resulted statistically higher than the healthy group, confirming that plasmatic PCT levels increase during SIRS process. No statistically differences were found between subgroups; this finding might be due to the small number of animals included in the subgroups. PCT seems to be a sensitive and specific marker of SIRS in horses. The limit of the study might be the number of cases included (n = 48). An increased study population is needed to investigate the role of PCT in being able to distinguish between septic and nonseptic SIRS in adult horses and to shortening antimicrobial treatment as already reported in humans.3, 6
  8 in total

Review 1.  Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis.

Authors:  Stefan Riedel
Journal:  Diagn Microbiol Infect Dis       Date:  2012-07       Impact factor: 2.803

2.  A new ELISA for the quantification of equine procalcitonin in plasma as potential inflammation biomarker in horses.

Authors:  Martin Rieger; Christian Kochleus; Dana Teschner; Daniela Rascher; Ann Kristin Barton; Arie Geerlof; Elisabeth Kremmer; Michael Schmid; Anton Hartmann; Heidrun Gehlen
Journal:  Anal Bioanal Chem       Date:  2014-06-14       Impact factor: 4.142

3.  Molecular cloning and expression of equine calcitonin, calcitonin gene-related peptide-I, and calcitonin gene-related peptide-II.

Authors:  Ramiro E Toribio; Catherine W Kohn; Gustavo W Leone; Charles C Capen; Thomas J Rosol
Journal:  Mol Cell Endocrinol       Date:  2003-01-31       Impact factor: 4.102

4.  Induction and characterization of endotoxin tolerance in equine peripheral blood mononuclear cells in vitro.

Authors:  Linda Frellstedt; Harold C McKenzie; Jennifer G Barrett; Martin O Furr
Journal:  Vet Immunol Immunopathol       Date:  2012-05-15       Impact factor: 2.046

5.  Evaluation of CALC-I gene (CALCA) expression in tissues of dogs with signs of the systemic inflammatory response syndrome.

Authors:  Massimo Giunti; Angelo Peli; Mara Battilani; Silvia Zacchini; Gianfranco Militerno; Cynthia M Otto
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2010-09-21

6.  Endotoxin increases plasma leptin and ghrelin levels in dogs.

Authors:  Zeki Yilmaz; Yesim Ozarda Ilcol; Ismail H Ulus
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

Review 7.  Is it the systemic inflammatory response syndrome or endotoxemia in horses with colic?

Authors:  James N Moore; Michel L Vandenplas
Journal:  Vet Clin North Am Equine Pract       Date:  2014-06-04       Impact factor: 1.792

Review 8.  Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.

Authors:  Anna Prkno; Christina Wacker; Frank M Brunkhorst; Peter Schlattmann
Journal:  Crit Care       Date:  2013-12-11       Impact factor: 9.097

  8 in total
  6 in total

Review 1.  Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?

Authors:  Ann Kristin Barton; Heidrun Gehlen
Journal:  Mediators Inflamm       Date:  2016-12-07       Impact factor: 4.711

2.  Plasma procalcitonin concentrations are increased in dogs with sepsis.

Authors:  Robert Goggs; Matthew Milloway; Roberta Troia; Massimo Giunti
Journal:  Vet Rec Open       Date:  2018-04-12

3.  Assessment of platelet biology in equine patients with systemic inflammatory response syndrome.

Authors:  Carolin Ehrmann; Julia Engel; Andreas Moritz; Katja Roscher
Journal:  J Vet Diagn Invest       Date:  2020-12-22       Impact factor: 1.279

4.  Can Procalcitonin Be Dosed in Bovine Milk Using a Commercial ELISA Kit?

Authors:  Valentina Meucci; Chiara Orsetti; Micaela Sgorbini; Federica Battaglia; Marta Cresci; Francesca Bonelli
Journal:  Animals (Basel)       Date:  2022-01-25       Impact factor: 2.752

5.  Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome.

Authors:  Kim Theuerkauf; Carmen Obach-Schröck; Carsten Staszyk; Andreas Moritz; Katja A Roscher
Journal:  J Vet Diagn Invest       Date:  2022-02-15       Impact factor: 1.569

6.  Reference intervals of acute phase proteins in healthy Andalusian donkeys and response to experimentally induced endotoxemia.

Authors:  Alejandro Perez-Ecija; Antonio Buzon-Cuevas; Raul Aguilera-Aguilera; Carlos Gonzalez-De Cara; Franciso J Mendoza Garcia
Journal:  J Vet Intern Med       Date:  2020-12-18       Impact factor: 3.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.